SCHEMBL7716778

SCHEMBL7716778

CCOC(=O)C(CC)C(C)CP(=O)(O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 2/20 0.34
ALDH1A1 P00352 4/20 0.33
LAP3 P28838 1/20 0.33
ALOX15 P16050 2/20 0.33
TSHR P16473 2/20 0.33
CYP3A4 P08684 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
METAP1 P53582 1/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
LMNA P02545 1/20 0.32
MGAM O43451 1/20 0.31
GAA P10253 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
SOAT1 P35610 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7718876 0.89 CYP2D6 (0.37) CYP2D6CYP2C9CYP2C19HSD17B10ALDH1A1
SCHEMBL6132143 0.81 CYP2D6 (0.41) CYP2D6CYP2C9CYP2C19HSD17B10ALDH1A1
SCHEMBL17617134 0.80 ALDH1A1 (0.42) CYP2C19HSD17B10ALDH1A1ALOX15TSHR
SCHEMBL17617126 0.80 ALDH1A1 (0.42) CYP2C19HSD17B10ALDH1A1ALOX15TSHR
SCHEMBL17617122 0.80 ALDH1A1 (0.42) CYP2C19HSD17B10ALDH1A1ALOX15TSHR
SCHEMBL7714685 0.77 METAP1 (0.42) CYP2D6CYP2C9CYP2C19ALDH1A1LAP3
SCHEMBL7715964 0.77 CYP2D6 (0.41) CYP2D6CYP2C9CYP2C19HSD17B10ALDH1A1
SCHEMBL235849 0.75 ALDH1A1 (0.50) HSD17B10ALDH1A1ALOX15TSHRLMNA
SCHEMBL7716769 0.75 CYP2D6 (0.42) CYP2D6CYP2C9CYP2C19HSD17B10ALDH1A1
SCHEMBL17617141 0.73 ALDH1A1 (0.43) CYP2C19HSD17B10ALDH1A1ALOX15CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed